EAM
VIRX

EverPoint Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

EverPoint Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-952
Closed -$1.3M – 573
2014
Q2 		$1.3M Buy
+952
New +$1.1M 0.03% 439

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EverPoint Asset Management's VIRX Position: Q3 2014 in Review

EverPoint Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2014, closing a stake of 952 shares — an estimated $1.3M sold.

EverPoint Asset Management first reported a position in VIRX in Q2 2014 and held it in 1 quarter. The position peaked at $1.3M in Q2 2014. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

  • EverPoint Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • EverPoint Asset Management sold 952 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $1.3M.
  • EverPoint Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • EverPoint Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.3M in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on EverPoint Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.